NEWSLETTER
June 2019

URANUS study country approval status

URANUS trial has been approved by the Ethics Committee and the Spanish Medicine Agency for the following 12 Spanish centres:

Principal Investigator	Centre	City
Joan Palou Redorta	Fundació Puigvert	Barcelona
Pablo Maroto Rey	Hospital de Sant Pau	Barcelona
Jorge García Rodríguez	Hospital Universitario Central de Asturias	Oviedo
Francisco Gómez Veiga	Hospital Universitario de Salamanca	Salamanca
Asier Leibar Tamayo	Hospital Infanta Sofía	Madrid
Sara Martínez Breijo	Hospital Juan Canalejo	A Coruña
Ignacio Osman García	Hospital Virgen del Rocío	Sevilla
Enrique Gallardo	Hospital Parc Taulí	Sabadell
Javier J. Burgos	Hospital Ramón y Cajal	Madrid
José Luis Rodríguez Escrig	Fundación IVO	Valencia
Rubén Campanario Pérez	Hospital de Jerez	Cádiz
José Antonio Portillo	Hospital Universitario de Valdecilla	Santander

The next step are the site agreements that need to be in place for all centres. Once this requirement has been fulfilled, initiations visits will be performed. Following Site Initiation, the approved sites will be ready to randomise patients online.

Austria, Italy, Slovakia, Portugal and Japan, are currently in the process of trial submission to the Ethics Committee.

URANUS recruitment status

Below, the start of trial recruitment. We noticed that in this start-up phase, patients were lost for inclusion due to multiple reasons including uncertainties about in/exclusion criteria and clinical staging. In case of doubt, please contact the trial Unit (CTU) (EUOG@lumc.nl) and Trial Coordinators (by email or mobile), and the CTU for a quick expert pathologists panel revision of the urine cytology and/or biopsy samples.



Total recruitment Hospital and patients included	Country	Open since
Haukeland University Hospital (3)	Norway	22-8-2018
Leiden University Medical Centre (1)	The Netherlands	28-5-2018
Radboud University Medical Centre (1)	The Netherlands	23-8-2018
Alrijne Ziekenhuis Leiderdorp (1)	The Netherlands	24-1-2019

Uranus Protocol Reminders

Patient Registration

Inclusion and exclusion criteria for URANUS patients require to perform some tests (i.e.. laboratory) that are not done routinely as standard of care in some centres, especially not in patients with poor renal function (URANUS Arm A, surgery only). However, all patients need to fulfil the inclusion criteria. To avoid protocol deviations, investigators must register all patients before starting treatment by using the electronic registration form via the URANUS e-CRF. Electronic registration ensures adherence to URANUS eligibility criteria.

DEMO e-CRF

A Demonstration e-CRF is available for investigators after national approval and before starting recruitment via EUOG CTU (EUOG@lumc.nl) in order to get familiar with the system.

Urgent Medical Questions regarding Patient Eligibility

For urgent medical questions investigators will have access to the telephone numbers of the study coordinators. Investigators should also send their question via e-mail to the EUOG Clinical Trial Unit (CTU).

	E-mail address	Telephone
Dr. Osanto (NL)	s.osanto@lumc.nl	+ 31 71 526 5122
Dr. Palou (ES)	jpalou@fundacio-puigvert.es	+ 34 93 416 9700
Dr. Maroto (ES)	JMaroto@santpau.cat	+ 34 93 556 5638/9
EUOG CTU	EUOG@lumc.nl	+ 31 71 526 4109

Centralized review of specimens by expert pathologists panel

There are currently different pathology tumor grading classifications for upper tract urothelial carcinoma and in some cases, the investigator had difficulties with the interpretation for the URANUS study (WHO 1973, WHO 2004 and The Paris System for Reporting Urinary Cytology). To enhance patient recruitment and support centers, a panel of three expert pathologists, Dr. Montironi, Dr. López Beltran and Dr. Gevaert, will provide help by reviewing tumor biopsy or urine cytology in case of uncertainty with regard to the proper classification. Pictures can be sent via EUOG CTU (EUOG@lumc.nl) using 3 magnifications 10x, 20x,40x for cytology samples and 4 magnifications 2.5x,10x, 20x,40x for biopsies. The report of one or more of the expert pathologists will be made available to the center very soon thereafter.

Intergroup collaboration between EUOG and Blokhin Russian Cancer Research Centre

EUOG and Blokhin Russian Cancer Research Centre in Moscow (BRCC) agreed to collaborate in order to increase the number of UTUC patients available for analysis.

URANUS new protocol version is available

URANUS new Protocol version NL3 (August 15, 2018) has been approved in the Netherlands and is available for country coordinators who want to submit to their country regulatory authorities. The aim of the new protocol version is to improve patient screening by changes in biopsy and cytology requirements.

Protocol version NL 2.2	New protocol version NL 3
Biopsy and /or cytology: positive biopsy for high grade tumor	Biopsy and /or cytology: positive biopsy : G2-G3 (WHO 1973), high grade (WHO 2004). G1 can only be accepted if there are clear diagnostic signs of invasion of the tumor on the CT scan, the biopsy is small and the grade difficult to assess. • in a patient who clearly has a T2 or T3 tumor and who has an obstructed ureter precluding performing a ureterostomy and getting an biopsy of selective urine for cytology • or in a T2-T3 tumor not easily accessible for a biopsy and (selective) urine such a patient may also be entered into the trial.

HORNA recruitment target has been reached

HORNA investigator initiated study: “Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (XTANDI) Androgen Receptor (AR)-Directed Therapy in Hormone-Naïve patients with Metastatic Prostate Cancer who have never before received Androgen Deprivation Therapy”.
HORNA study is closed for recruitment after enrolment of the target number of patients (n=60). The aim of the HORNA study is to evaluate the performance of Choline PET/CT and/or WB MRI compared to traditional serial PSA measurements, bone scan and CT scan of thorax and abdomen to early assess antitumor responses to enzalutamide in hormone-naïve prostate cancer patients. CTC and ctDNA measurements are also being assessed regularly during the course of treatment. HORNA is now collecting patients follow-up information over 2 years.

EUOG International Database

EUOG has initiated an international database consortium for upper tract urothelial carcinoma and bladder cancer. Please contact the CTU if you are interested to join.

With kind regards,
Study Coordinating Team